<DOC>
	<DOCNO>NCT01965496</DOCNO>
	<brief_summary>Polyethylene Glycol Loxenatide ( PEX168 ) new human glucagon-like peptide 1 ( GLP-1 ) analogue create basis Exenatide modify polyethylene glycol ( PEG ) . This study aim evaluate whether titration mode administration could reduce incidence adverse reaction PEX168 , also decide observe long-term continuous administration PK/PD correlation .</brief_summary>
	<brief_title>A Phase I Study Polyethylene Glycol Loxenatide Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Has diagnose type 2 diabetes mellitus 2 . Has treat either : diet exercise alone , stable regimen one combination two oral antihyperglycaemic agent ( except TZDs ) , minimum 3 month prior study start . 3 . Has HbA1c 7.5 % 11.0 % , inclusive . 4 . Is 20 72 year old , inclusive . 5 . Has body mass index ( BMI ) 19 kg/m2 35 kg/m2 , inclusive . 1 . Skin test PEX168 positive . 2 . Is currently treat follow excluded medication : GLP1 GLP1 analogues prior study start ; Insulin within 6 month prior study start ; Growth hormone within 6 month prior study start ; Abuse drug alcohol within 6 month prior study start ; Any clinical trial drug medical instrument within 3 month prior study start ; Systemic corticosteroid oral , parenteral , intraarticular route Any drug weight loss operation lead weight instable within 2 month prior study start ; Any drug may interfere evaluation safety efficiency investigate drug , drug herbal medicine may result toxicity main organ prior study start ; 3 . A history evidence follow : Severe hypoglycemia history ( e.g. , sleepiness , consciousness disorder , deliration , coma lead hypoglycemia ) Type 1diabetes , monogenic diabetes , diabetes result pancreatic injury , secondary form diabetes ( e.g. , Cushing 's syndrome acromegalyassociated diabetes ) . Other endocrine disease ( e.g. , hyperthyreosis , hypothyroidism ) Acute chronic gastrointestinal disease suitable trial evaluate investigator . Hypertension SBP &gt; 140mmHg , and/or DBP &gt; 90mmHg antihypertensive therapy . Severe cardiovascular disease history include congestive heart failure ( NYHA III IV ) , unstable angina , stroke TIA , myocardial infarction , sustain clinically relevant ventricular arrhythmia , coronary artery bypass surgery percutaneous coronary intervention . Acute chronic pancreatitis history , pancreas injury history , high risk factor may result pancreatitis . Malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , regardless whether evidence local recurrence metastasis . Medullary thyroid carcinoma history , multiple endocrine neoplasia history . Acute metabolic complication ketoacidosis , lactic acidosis , hyperosmolar state ( coma ) , maculopathy , instability proliferative retinopathy within past 6 month . Weight change 10 % within 3 month prior study start . hepatitis B positive , hepatitis C antibody positive , HIV antibody positive , syphilis antibody positive . 4 . Any following significant laboratory abnormality : Alanine aminotrasferase ( ALT ) and/or asparatate aminotransferase ( AST ) &gt; 2*upper limit normal ( ULN ) , and/or total bilirubin &gt; 1.5*ULN , confirm repeat measure ; Creatinine &gt; upper limit normal , confirm repeat measure , and/or proteinurea &gt; ++ 24 hour urinary protein quantitative â‰¥1g . Thyroid dysfunction unsuitable trial evaluate investigator ; Hemodlastase &gt; upper limit normal , confirm repeat measure ; 5 . Male female fertility reluctant take contraceptive method test , pregnancy lactate woman ; 6 . Any situation may result withdrawal subject bring significant risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PEX168</keyword>
	<keyword>Phase I</keyword>
	<keyword>titration</keyword>
</DOC>